Self-Emulsifying Lipid Composition for Liver Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid and its derivatives face challenges in reaching their biological targets due to cellular membrane penetration issues and hindered bioavailability, particularly in the liver, and lack improved pharmacokinetic properties such as gender differences, individual variability, and food effects.
Innovation Solution
A composition comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, an ester derivative, a triglyceride, and a surfactant, forming a self-microemulsifying or nanoemulsifying drug delivery system that enhances solubilization, digestion, and absorption, while improving pharmacokinetics by increasing portal vein uptake and reducing systemic exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the active ingredient is formulated as a carboxylic acid, then it can bind to cellular targets, but it cannot cross cell membranes effectively
Solution Approach 1:
The molecule is segmented into two functional parts: a carboxylic acid group for target binding and an ester prodrug moiety for membrane penetration. The ester group enables passive diffusion across cell membranes, while the carboxylic acid group maintains affinity for cellular targets. Intracellular esterases then convert the prodrug back to the active carboxylic acid form.
Solution Approach 2:
The ester prodrug acts as an intermediary form that facilitates membrane crossing. It serves as a bridge between the extracellular environment and intracellular target, being converted by intracellular esterases into the active carboxylic acid form that can bind to cellular targets.
2Ease of operation
If the active ingredient is protected as an ester prodrug, then it can cross cell membranes, but it requires enzymatic hydrolysis to become active
Solution Approach 1:
The prodrug design leverages the body's existing intracellular esterases to perform the conversion from ester prodrug to active carboxylic acid form. The system uses the body's natural enzymatic machinery rather than requiring external activation, making the activation process automatic and location-specific within cells.
3Device complexity
If standard oil formulations are used, then the formulation is simple, but the bioavailability and absorption are limited
Solution Approach 1:
The formulation uses a composite system combining the ester prodrug with specific excipients including medium-chain triglycerides and surfactants. This composite formulation creates self-microemulsifying or self-nanoemulsifying properties that dramatically enhance solubilization and bioavailability compared to simple oil formulations.
Solution Approach 2:
The invention changes the chemical parameter of the active ingredient from carboxylic acid to ester prodrug form. This parameter change fundamentally alters the molecule's properties, enabling membrane penetration while maintaining target affinity, and when combined with emulsifying excipients, achieves superior bioavailability.
4Reliability
If the carboxylic acid form is used, then it has biological activity, but it shows variability due to food effects and gender differences
Solution Approach 1:
The ester prodrug is designed to be pre-activated by intracellular esterases before the active carboxylic acid can exert its biological effect. This preliminary enzymatic activation step occurs uniformly within cells regardless of external factors like food intake or gender, leading to more consistent pharmacokinetics and reduced variability in biological response.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly increases the concentration of the active pharmaceutical ingredient in the micellar phase by over 50% compared to standard oil formulations, providing enhanced bioavailability and absorption, and maintains consistent pharmacokinetics with reduced food and gender-related variability.
Implementation Method 1
a surfactant
Implementation Method 2
forming a self-microemulsifying or nanoemulsifying drug delivery system
Implementation Method 3
forming a self-microemulsifying or nanoemulsifying drug delivery system
Implementation Method 4
significantly increases the concentration of the active pharmaceutical ingredient in the micellar phase
Data Source
AI summary
Compositions comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, an ester derivative, or a pharmaceutically acceptable salt thereof; a triglyceride; and a surfactant, as well as methods for their use. The present disclosure further relates to self-emulsifying drug delivery systems, such as SEDDS, SMEDDS, or SNEDDS comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid.